Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Intranasal (IN) Ketamine in Treatment-Resistant Depression (TRD)


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT01304147

Organisation Name: Icahn School of Medicine at Mount Sinai

Overal Status: Completed

Start Date: October 2011

Last Update: February 8, 2017

Lead Sponsor: James Murrough

Brief Summary: The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).

Conditions:
  • Major Depressive Disorder


Total execution time in seconds: 0.18254804611206